: iStockAnalyst.com Symbols Feed

Insulet Corporation

Sun, 02 Dec 2007 19:33:07 GMT

PODD - Insulet Corporation, a medical device company, engages in the development, manufacture, and marketing of insulin infusion system for people with insulin-dependent diabetes in the United States. It offers OmniPod Insulin Management System, which consists of its OmniPod disposable insulin infusion device and handheld wireless personal...[More...]

Insulet Corporation Announces Pricing of Public Offering

Thu, 29 Oct 2009 22:48:00 GMT

Insulet Corporation (NASDAQ: PODD) today announced the pricing of its public offering of 6,000,000 shares of common stock at $10.25 per share.
Insulet currently expects to use the net proceeds of this offering for general corporate purposes, which may include the repayment of certain outstanding debt obligations.
J.P. Morgan Securities Inc. is acting as sole book-running manager of the offering and Canaccord Adams Inc. and JMP Securities LLC are acting as co-managers of the offering.

[More...]

Insulet Reports Third Quarter 2009 Results

Mon, 26 Oct 2009 20:49:00 GMT

Insulet Corporation (NASDAQ: PODD), the leader in tubing-free insulin pump technology with its OmniPod(R) Insulin Management System, today announced financial results for the three and nine months ended September 30, 2009.
Operating loss for the third quarter of 2009 was $13.5 million, a 32% improvement compared to operating loss of $19.8 million in the third quarter of 2008.
Net loss for the third quarter of 2009 was $24.7 million, or $0.88 per share, compared to a net loss of $21.7 million, or $0.78 per share, for the third quarter of 2008.

[More...]

Insulet Amends Deerfield Credit Facility and Issues Stock

Mon, 28 Sep 2009 13:50:00 GMT

Insulet Corporation (NASDAQ: PODD), the leader in tubing-free insulin pump technology with its OmniPod(R) Insulin Management System, today announced that it has amended its $60 million credit facility with Deerfield Management Company, which was signed in March 2009.
Under the terms of the amended agreement, Insulet will repay the $27.5 million of currently outstanding debt by issuing 2,855,659 shares of common stock to Deerfield at a price of $9.63 per share.
"This transaction enhances Insulet's financial flexibility and enables us to continue to drive adoption of the OmniPod Insulin Management System around the world," said Duane DeSisto, President and Chief Executive Officer of Insulet Corporation.

[More...]

Insulet Appoints Peter J. Devlin as Chief Commercial Officer

Mon, 17 Aug 2009 19:55:00 GMT

Insulet Corporation , the leader in tubing-free insulin pump technology with its OmniPod Insulin Management System, today announced the appointment of Peter J. Devlin as Chief Commercial Officer. In this newly created role, Mr. Devlin will lead the Company's Sales and Marketing, Business Development, Clinical Research and Customer Care operations.[More...]

Insulet Corporation to Present at Upcoming Investor Conferences

Fri, 07 Aug 2009 15:30:00 GMT

Insulet Corporation , the leader in tubing-free insulin pump technology with its OmniPod Insulin Management System, today announced the company will participate in upcoming investor conferences. These conferences include:[More...]

Bottomline Technologies Reports Fourth Quarter Results

Wed, 05 Aug 2009 20:50:00 GMT

Bottomline Technologies (NASDAQ: EPAY), a leading provider of collaborative payment, invoice and document automation solutions, today reported financial results for the fourth quarter and fiscal year ended June 30, 2009.
Core net income for the fourth quarter was $5.3 million after excluding acquisition-related expenses of $4.1 million and equity-based compensation and restructuring expenses of $4.7 million.
"We had a very strong fourth quarter in terms of both reported financial results and strategic advancement," said Rob Eberle, President and CEO of Bottomline Technologies.

[More...]

Insulet Reports Second Quarter 2009 Results

Tue, 04 Aug 2009 19:56:00 GMT

Insulet Corporation , the leader in tubing-free insulin pump technology with its OmniPod Insulin Management System, today announced financial results for the three and six months ended June 30, 2009.[More...]

Insulet Corporation to Report Second Quarter 2009 Financial Results on Tuesday, August 4, 2009

Mon, 20 Jul 2009 21:36:00 GMT

Insulet Corporation , the leader in tubing-free insulin pump technology with its OmniPod Insulin Management System, announced plans to release its financial results for the second quarter 2009 on Tuesday, August 4, 2009 after the close of the financial markets.Insulet will also host a conference call at 5:00 p.m. Eastern Time on Tuesday, August 4, 2009 to discuss its second quarter 2009 financial results. During the conference call, material information concerning the Company, its operations, strategies and prospects may be discussed.To listen to the conference call, please dial 866-804-6921 for domestic callers and 857-350-1667 for international callers. The passcode is 29253441. A replay of the conference call will be available two hours after the start of the call through August 11, 2009 by dialing 888-286-8010 and 617-801-6888 , passcode 66405735. An online archive of the conference call will also be available by accessing the Investor Information section of the company's website at http://investors.insulet.com. About Insulet CorporationInsulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA. Contact:[More...]

Insulet Establishes Eco-Friendly Disposal Program for the OmniPod(R) Insulin Management System

Wed, 08 Jul 2009 10:56:00 GMT

Insulet Corporation , the leader in tubing-free insulin pump technology, announced today that the Company is introducing an environmentally friendly disposal program for its OmniPod Insulin Management System. The Eco-Pod program will reduce the impact of used Pods on the environment, preventing hazardous waste from unnecessarily entering landfills. It is the industry's first program for the environmentally safe disposal of insulin pump components.[More...]